ADVERTISEMENT
Aaron Lisberg, MD, On Treatment Approaches for Oncogene-Driven NSCLC
11/20/2020
Dr Lisberg discusses when to use checkpoint inhibitor therapy in patients with targetable mutations in non–small-cell lung cancer (NSCLC), a recap of his presentation at the virtual 2020 Personalized Therapies in Thoracic Oncology meeting.
Advertisement
Advertisement
Advertisement
Advertisement
Advertisement
Advertisement
Advertisement
Advertisement
Advertisement
Advertisement
Advertisement
Visit the OLN Excellence Forums
Advertisement
Advertisement
Advertisement